|
|
Volumn 88, Issue 5, 2001, Pages 662-668
|
|
Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIINFECTIVE AGENT;
LITHIUM GAMOLENATE;
UNCLASSIFIED DRUG;
UNSATURATED FATTY ACID;
ADULT;
AGED;
ARTICLE;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DOSE RESPONSE;
DRUG MEGADOSE;
HEMOLYSIS;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
METASTASIS;
PANCREAS ADENOCARCINOMA;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL RATE;
TREATMENT OUTCOME;
ADENOCARCINOMA;
ADMINISTRATION, ORAL;
ADOLESCENT;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC AGENTS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FATTY ACIDS, UNSATURATED;
GAMMA-GLOBULINS;
HUMANS;
INFUSIONS, INTRAVENOUS;
MIDDLE AGED;
PANCREATIC NEOPLASMS;
SURVIVAL ANALYSIS;
|
|
EID: 0035666362
PISSN: 00071323
EISSN: None
Source Type: Journal
DOI: 10.1046/j.0007-1323.2001.01770.x Document Type: Article |
|
Times cited : (39)
|
|
References (20)
|
